PRACTICAL ONCOLOGY JOURNAL ›› 2009, Vol. 23 ›› Issue (6): 541-544.doi: 10.3969/j.issn.1002-3070.2009.06.012

Previous Articles     Next Articles

Clinical observation of paclitaxel liposome and cisplatin in the treatment of recurrent ovarian cancer

ZHANG ShuYao, YANG Yuxian, ZHU Zhiwei, ZHOU Li   

  1. Medical College of Shantou University, Tumor Hospital, Shantou 515031
  • Received:2009-11-17 Online:2009-12-25 Published:2012-02-21

Abstract: Objective To observe the Results of paclitaxel liposome and cisplatin in the treatment of recurrent ovarian cancer.Methods 82 cases of recurrent ovarian cancer were divided into 2 groups, experimental group(40 cases)and control group(42 cases), each experimental group was given paclitaxel liposome treatment 135mg/m2, 1, 8-day intravenous infusion(intravenous);cisplatin 100mg, at the first intravenous infusion of 1-5 days;control group, 1500mg of fluorouracil and cisplatin 100mg, given in accordance with conventional doses.Epithelial ovarian cancer antigen(CA125)value, narrow focus, the survival rate, the sensitivity of different pathological types, as well as adverse reactions were observed.Results CA125 decline in the rate of 27 percent, the rate of lesion reducing was 32%, 1-year survival rate of 72%, in the control group were 10%, 10%and 35% respectively, the difference was significant(P <0.05).Clear cell carcinoma was more sensitive to paclitaxel liposome than that of serous carcinoma.The main adverse reactions of the experimental group were diarrhea, vomiting, neutropenia, intestinal obstruction and neurotoxicity.Conclusion Paclitaxel liposomes and cisplatin could be an effective treatment program for recurrent ovarian cancer.

CLC Number: